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Summary 
6-Aminolevulinic acid synthetase, the initial and rate limiting step in 
hepatic heme synthesis, is induced by both benepyrene and phenobarbital. In- 
duction of this enzyme by benzpyrene results in the stimulation of glycine-2- 
14C incorporation into hepatic microsomal heme in vivo and in the induction of -- 
cytochrome P-450 and N-demethylase activity. 3-Amino-1,2,4-triazole, an in- 
hibitor of the second step in hepatic heme synthesis, prevents the stimulation 
of hepatic heme synthesis and the induction of P-450 and N-demethylase activity. 
It is suggested that induction of 6-aminolevulinic acid synthetase leading to 
increases in hepatic heme synthesis may be the mechanism by which benzpyrene 
induces cytochrome P-450 and certain hepatic microsomal oxidations. 
Pretreatment of animals with 3,4-benzpyrene (BP) and other polycyclic 
aromatic hydrocarbons such as 3-methylcholanthrene results in increased hepatic 
microsomal levels of cytochrome P-450 and in the induction of the hepatic 
microsomal oxidations of certain drugs and carcinogens (l-5). Although the 
exact mechanism by which induction occurs remains to be elucidated, stimulation 
of both heme synthesis and protein synthesis are undoubtedly essential to the 
induction process since, at least during the initial stages of induction, there 
appears to be a good correlation between increases in P-450 and certain micro- 
somal oxidations (10). 
Hepatic mitochondrial 6-aminolevulinic acid synthetase (AU synthetase) 
is the initial and rate limiting step in hepatic heme synthesis (6,7). Pheno- 
barbital (PB) has been demonstrated to induce ALA synthetase in chick embryo 
liver cells in culture and in the livers of experimental animals (6,8,9). Pre- 
vious studies in this laboratory (10) have suggested that PB might exert its 
stimulatory effect on drug metabolism by increasing the rate of hepatic heme 
synthesis which directs the increased synthesis of cytochrome P-450. Since the 
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administration of BP also results in increases in the level of cytochrome P-450 
in hepatic microsomes, stimulation of hepatic heme synthesis vfa induction of 
ALA synthetase is also a possible mechanism for the induction of the hepatic 
microsomal drug-metabolizing system by BP. 
The herbicide 3-amino-1,2,4-triazole (AT), an inhibitor of the second 
step in hepatic heme synthesis, has been employed to inhibit hepatic heme syn- 
thesis and to prevent PB from stimulating hepatic heme synthesis (10). AT has 
also been demonstrated to inhibit the induction of certain hepatic microsomal 
oxidations produced by either PB (10111,12) or by methylcholanthrene (11). 
The present report describes the stimulatory effect of BP on rat hepatic 
ALA synthetase, hepatic heme synthesis, cytochrome P-450 synthesis and on the 
N-demethylation of 3-methyl-4-monomethylaminoazobenzene (3-CH3-M4B). The 
inhibitory effect of AT on these inductions, and the effects of both BP and AT 
on the microsomal levels of cytochrome b5 and NADPH-cytochrome c reductase 
activity are also described. 
Methods 
Male Holtzman rats weighing 130 to 170 g were used throughout these studies. 
Drugs were administered intraperitoneally in the following doses: BP, 20 mg/kg 
in corn oil; AT, 3 g/kg in saline; and PB, 40 mg/kg in saline. Control animals 
received an equal volume of saline and/or corn oil. Rats were fasted for 24 hr 
prior to sacrifice but were given water ad libitum. -- In all experiments, the 
livers from two rats which received identical treatments were pooled upon 
homogenization. ALA synthetase activity was determined in hepatic homogenates 
by a modification of the method of Marver et al. (13). Methods for the 
preparation of microsomes and measurements of the N-demethylation of 3-CH3-MB, 
the activity of NADPH-cytochrome c reductase, the content of cytochromes P-450 
and b5 and the incorporation of isotopic precursor into hepatic microsomal heme 
have been described previously (10). 
Results 
BP administration results in the induction of microsomal cytochrome 
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Table 1. Effects of benzpyrene (BP) and aminotriazole (AT) on th: incorporation 
of glycine-2-14 C into hepatic microsomal heme in vivo. 
Pretreatment Percent of control 2 
BP 131.8 + 1.7 3 
AT 86.1 + 2.8 3 
BP + AT 109.0 + 2.1 
1 Rats received intraperitoneally a 45-min. 
pulse-dose of 30 PC of glyctne-P-l% 16 hr. 
after the administration of drugs. The 
control value was 196.9 cpm/mpmole of 
protoheme. 
r, alues represent the mean + S.E.M. of at 
least three experiments. 
3 p < 0.05. 
P-450 and the induction of certain microsomal oxidations (1,4,5). I f  this 
phenomenon is related to an increase in the synthesis of cytochrome P-450, a 
stimulation of hepatic microsomal heme synthesis should be observed after the 
administration of BP to rats. Table 1 shows that there is a 32% stimulation 
of the in vivo incorporation of glycine-2- 14 C -- into hepatic microsomal heme 16 
hr after BP administration. This stimulation is prevented by AT, an inhibitor 
of ALA dehydratase (10,14), the second step in hepatic heme synthesis. AT has 
previously been observed to inhibit the PB-induced increase in hepatic heme 
synthesis (10). 
The mechanism for the induction of heme synthesis and cytochrome P-450 
may be reIated to an increase in ALA synthetase activity. Table 2 shows that 
both BP and PB produce a marked induction of hepatic ALA synthetase activity 
16 hr after administration to rats. The induction is not affected by AT, nor 
does AT alone alter the level of activity of this eneyme. This indicates that 
both BP and PB induce cytochrome P-450 by stimulating hepatic microsomal heme 
synthesis via induction of ALA synthetase. PB has also been shown to stimulate 
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Table 2. Effects of benzpyrene (BP), phenobarbital (PB), ani aminotriazole (AT) 
pretreatments on hepatic ALA synthetaae activity. 
Pretreatment mpmoles ALA formed/ g of liver/hr Percent of control 
Control 15.3 + 0.4 2 
AT 16.0 +_ 0.5 104.9 2 1.7 
BP 79.8 + 9.7 522.4 + 15.8 3 
BP + AT 74.3 _+ 12.1 519.2 + 23.6 3 
PB 225.2 + 28.7 1449.0 2 87.1 3 
PB + AT 193.8 f  15.8 1281.5 +, 52.6 3 
1 Drugs were administered 16 hr. prior to sacrifice. 
2 Values represent the mean + S.E.M. of at least three 
experiments. 
3 p < 0.05. 
synthesis of microsomal heme (10) and AT inhibits this stimulation. Treatment 
of rats with actinomycin D (3 mg/kg) at the same time as either BP or PB 
completely prevented the induction of ALA synthetase. 
Table 3 shows that BP induces cytochrome P-450 and the N-demethylation of 
3-CH3-k%B. That these effects are due to an enhancement of hepatic microsomal 
heme synthesis is indicated from the observation that AT significantly 
antagonizes the increases of both P-450 content and 3-CH3-MAB N-demethylase 
activity. The effects of AT do not result from either interference with the 
assay OK from a direct inhibition (10). However AT begins to lose its effect 
after the first 24 hr. This is likely due to increased levels of endogenous 
ALA which would reverse the inhibition. 
Although BP pretreatment results in an enhancement of hepatic heme 
synthesis and an increase in cytochrome P-450 levels, there was no observable 
effect by either BP or AT on the hepatic microsomal level of cytochrome b5 
during the first 48 hr of treatment (Table 3). This is similar to the effect 
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Table 3. Effects of benzpyrene (BP) and aminotriazole (AT) pretreatment5 on 
microsomal he 
c reductase. T” 
proteins, 3-CH3-mB N-demethylase and NADPH-cytochrome 
Measurement 
Duration 
of Percent of control 
2 
Treatment BP AT BP + AT 
P-450 3 
Cytochrome b5 4 
N-demethylase 3-CH3-M4B 5 
NADPH-cytoch ome 
c reductase f  
24 164 2 13* 70 +, 5* 114+ 8 
48 229 + 19* 782 3* 162 z 15* 
24 123 + 23 101 + 15 126 2 19 
48 127 z 22 117 +_ 31 124 +_ 16 
24 151 2 17* 76 + 5* 115 + 18 
48 212 + 21* 76 z lo* 153 z 12* 
24 113 + 10 116 + 10 119 + 9 
48 121 2 13 113 z 13 138 z 17 
1 Drugs were administered every 24 hr. 
‘Values represent the mean 1 S.E.M. of at least three experiments. 
3 Control value was 0.023 AOD 450-490 mu/mg protein. 
4 Control 
5 
value was 0.096 mumoles cytochrome b5/mg protein. 
Control value was 0.69 mumoles HCHO formed/mg proteinlmin. 
6 Control value was 42 mqoles cytochrome c reduced/mg protein/min. 
* 
p < 0.05. 
of PB (10,15). Unlike PB, BP does not induce NADPH-cytochrome c reductase 
activity (Table 3), the microsomal flavoprotein which may be responsible for the 
reduction of cytochrome P-450. This may indicate that in those oxidations 
induced by BP, NADPH-cytochrome c reductaee is not a rate limiting component. 
On the other hand, NADPH-cytochrome c reductase activity may not be represen- 
tative of NADPH-cytochrome P-450 reductase activity (16). 
Discussion 
Within 24 hr after the administration of BP to rats there is an increase 
in the level of microsomal cytochrome P-450 and an induction of certain hepatic 
microsomal oxidations (1,4,5). The proximal mechanism by which BP and related 
compounds produce this effect remains to be elucidated. However, the present 
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studies suggest that, like PB (lo), BP produces a stimulation of hepatic 
microsomal heme synthesis through the enhancement of ALA synthetase activity. 
This leads to an increased synthesis of cytochrome P-450 and the increase in 
certain microsomal oxidations. However, the species of cytochrome P-450 induced 
by BP and related compounds may be different from that induced by PB (2,3, 17) 
which may reflect the fact that certain protein moieties confer specificity to 
P-450. BP and PB may also influence the synthesis of these apocytochromes. 
PA has been demonstrated to induce the rate controlling step in hepatic 
heme synthesis, ALA synthetase (6,8,9), and has also been demonstrated to 
stimulate hepatic microsomal heme synthesis (9,lO). The present studies have 
demonstrated that BP similarly produces an induction of ALA synthetase and a 
stimulation of hepatic microsomal heme synthesis. The latter event is abolished 
by AT, although AT does not prevent the induction of ALA synthetase. Thus, it 
appears that both PB and BP stimulate hepatic heme synthesis through the 
induction of ALA synthetase. 
Further support for the postulate that induction of the drug-metabolizing 
system is dependent upon heme synthesis is seen from the data on the induction 
of cytochrome P-450 and 3-C I$-MAB N-demethylation by BP. When AT is adminis- 
tered together with BP, the stimulatory effects of BP are significantly reduced 
or prevented. Since AT exerts its effect on heme synthesis exclusive of an 
effect on protein synthesis and since any direct inhibitory effect of AT on 
microsomal drug metabolism is minimal (lo), these results suggest that the 
stimulation of hepatic heme synthesis may be the mechanism by which BP induces 
the hepatic microsomal drug-metabolizing system. 
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